Olanzapine enhances the response of PD-(L)1 inhibitor immunotherapy: A retrospective efficacy analysis in advanced malignancies

Read full text Summarise with VIRAT
Authors: Yan-ling Yi, Meng-xue Mei, Hai-hui Wang, J. Ye, Zhen-jie Huang, Sha Zhao, An-wen Liu, Long Huang
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This retrospective cohort study explores olanzapine's immunomodulatory role and clinical impact in patients with advanced cancer on PD-(L)1 inhibitors, given that chronic stress may impair immune checkpoint inhibitor (ICI) efficacy. Among 1933 patients with advanced cancer receiving PD-(L)1 inhibitors + chemotherapy (2018–2022), 99 received concurrent olanzapine for chemotherapy-induced nausea. After excluding 58 cases, 41 olanzapine-treated patients were propensity score-matched (PSM) for age, gender, and cancer type. Survival outcomes were analyzed via Kaplan-Meier curves and log rank tests. The olanzapine cohort showed higher objective response rate (ORR) (39.02% vs. 26.83%), comparable median PFS (9 vs. 6 months, p = 0.057), and significantly longer median OS (28 vs. 9 months, p = 0.019). Multivariate analysis confirmed olanzapine correlated with prolonged OS (HR = 0.510, 95% CI:0.282–0.917, p = 0.026). Olanzapine may enhance survival benefits in patients with advanced cancer undergoing PD-(L)1 inhibitor therapy.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Cancer Stress Anesthesia and Immune Response Immunotherapy and Immune Responses

Publication details

Journal / source
iScience
Volume
29
Issue
5
Pages
115568–115568
Publication date
2 April 2026
Language
EN